Booster Needed for Delta and Lambda Variants
Scientists may have underestimated the coronavirus. In the beginning, they said mutated versions shouldn’t be much of a problem—until Alpha spiked last fall. Then, Beta made young people sicker. And
Scientists may have underestimated the coronavirus. In the beginning, they said mutated versions shouldn’t be much of a problem—until Alpha spiked last fall. Then, Beta made young people sicker. And
Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly
First Florida Patient to Receive Biogen Aducanumab Infusion Read More »
According to the CDC, currently, there are four notable COVID-19 variants in the United States: B.1.1.7 (Alpha): This variant was first detected in the United States in December 2020. It
The COVID-19 Delta variant is extremely contagious and responsible for about 1 in 5 COVID-19 cases in the United States, and cases have doubled in the last two weeks, according
What do Scientists Know about the Delta Variant? Read More »
In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause
Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the
Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA. They approved
Last week Sage Therapeutics, Inc. and Biogen Inc. announced the results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor. Essential Tremor (ET)
Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study Read More »
Eli Lilly’s clinical trial of the experimental drug donanemab appears to have successfully slowed cognitive decline in patients with the early symptoms of Alzheimer’s. The TRAILBLAZER-ALZ clinical trial was a
Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon Read More »
First Choice Neurology, the nation’s largest single-specialty private neurology provider, announces the launch of Neuro2Go, an on-demand, face-to-face chat service which offers health consumers everywhere the opportunity to discuss a